Oncology

The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.

The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.

The findings suggest that a patient’s diet may impact their ability to combat head and neck cancer.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Unintentional weight loss may allow physicians to detect cancer sooner.

A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.

Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.

Top news of the day from across the health care landscape.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacists Director at Florida Cancer Specialists, discusses important considerations for managing oral chemotherapy care plans and improving adherence in patients.

Annual meeting explores how to overcome the challenges with patient care that community oncology practices face on a daily basis.

Top news of the week from Specialty Pharmacy Times.

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.

Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.

Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.

Top news of the week from Specialty Pharmacy Times.

The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Julianne Orr, PharmD, from the Indiana University Health Simon Cancer Center, discusses how pharmacists can help patients who are transitioning from an infusion product to an oral chemotherapy.

US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.

The therapy is a combination of a checkpoint drug, nivolumab, and a new immune stimulation drug, ALT-803.

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.

A novel chimera targets the growth factors responsible for certain types of breast cancer.

Alcohol-dependent patients with hepatitis C virus comorbidity found to have greater deficits in the frontal, precentral, superior, and orbital volumes.